Literature DB >> 18244997

Value based pricing for NHS drugs: an opportunity not to be missed?

Karl Claxton1, Andrew Briggs, Martin J Buxton, Anthony J Culyer, Christopher McCabe, Simon Walker, Mark J Sculpher.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 18244997      PMCID： PMC2223028          DOI： 10.1136/bmj.39434.500185.25

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  6 in total

1.  The pharmaceutical price regulation scheme.

Authors:  Joe Collier
Journal:  BMJ       Date:  2007-03-03

2.  Parliamentary review asks NICE to do better still.

Authors:  Joe Collier
Journal:  BMJ       Date:  2008-01-12

3.  Dangerous omissions: the consequences of ignoring decision uncertainty.

Authors:  Susan C Griffin; Karl P Claxton; Stephen J Palmer; Mark J Sculpher
Journal:  Health Econ       Date:  2011-02       Impact factor: 3.046

Review 4.  Using value of information analysis to prioritise health research: some lessons from recent UK experience.

Authors:  Karl P Claxton; Mark J Sculpher
Journal:  Pharmacoeconomics       Date:  2006       Impact factor: 4.981

5.  Searching for a threshold, not setting one: the role of the National Institute for Health and Clinical Excellence.

Authors:  Anthony Culyer; Christopher McCabe; Andrew Briggs; Karl Claxton; Martin Buxton; Ron Akehurst; Mark Sculpher; John Brazier
Journal:  J Health Serv Res Policy       Date:  2007-01

6.  OFT, VBP: QED?

Authors:  Karl Claxton
Journal:  Health Econ       Date:  2007-06       Impact factor: 3.046
  6 in total
  48 in total

1.  Cost-effectiveness analysis of KRAS testing and cetuximab as last-line therapy for colorectal cancer.

Authors:  Takeru Shiroiwa; Yoshiharu Motoo; Kiichiro Tsutani
Journal:  Mol Diagn Ther       Date:  2010-12-01       Impact factor: 4.074

Review 2.  International comparison of comparative effectiveness research in five jurisdictions: insights for the US.

Authors:  Adrian R Levy; Craig Mitton; Karissa M Johnston; Brian Harrigan; Andrew H Briggs
Journal:  Pharmacoeconomics       Date:  2010       Impact factor: 4.981

3.  Drugs, money and society (Part II).

Authors:  Tom Walley
Journal:  Br J Clin Pharmacol       Date:  2010-09       Impact factor: 4.335

4.  Should the Lambda (λ) Remain Silent?

Authors:  Hossein Haji Ali Afzali; Jonathan Karnon; Mark Sculpher
Journal:  Pharmacoeconomics       Date:  2016-04       Impact factor: 4.981

5.  PPRS: Not dead yet.

Authors:  Jim Furniss
Journal:  BMJ       Date:  2008-02-23

6.  Value of information and pricing new healthcare interventions.

Authors:  Andrew R Willan; Simon Eckermann
Journal:  Pharmacoeconomics       Date:  2012-06-01       Impact factor: 4.981

7.  Tendering and value-based pricing: lessons from Italy on human papilloma virus vaccines.

Authors:  Livio Garattini; Katelijne Van de Vooren; Nick Freemantle
Journal:  J R Soc Med       Date:  2014-01       Impact factor: 5.344

8.  Reading a cost-effectiveness or decision analysis study: Five things to consider.

Authors:  Kate C Young; Adam G Kelly; Robert G Holloway
Journal:  Neurol Clin Pract       Date:  2013-10

9.  Criteria for fairly allocating scarce health-care resources to genetic tests: which matter most?

Authors:  Wolf H Rogowski; Scott D Grosse; Jörg Schmidtke; Georg Marckmann
Journal:  Eur J Hum Genet       Date:  2013-08-07       Impact factor: 4.246

Review 10.  Market access of cancer drugs in European countries: improving resource allocation.

Authors:  Kim Pauwels; Isabelle Huys; Minne Casteels; Katelijne De Nys; Steven Simoens
Journal:  Target Oncol       Date:  2013-11-19       Impact factor: 4.493
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.